Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2025-09-19 Major Shareholding Noti…
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
Franchissements de seuils et déclaration d'intention
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding the disclosure of shareholding threshold crossings and the formation of a concert party (action de concert) by shareholders of OSE IMMUNOTHERAPEUTICS. It details the specific number of shares and voting rights held by various parties, the intent behind the concert, and the terms of a shareholder pact. This falls under the category of Major Shareholding Notification (MRQ), as it reports significant changes in ownership and voting control thresholds as required by French commercial law.
2025-09-19 French
Déclaration d'intention
AGM Information Classification · 95% confidence The document is an official notice filed with the AMF (Autorité des marchés financiers) regarding a 'Déclaration d'intention' (Declaration of Intent) under Article L. 233-7 of the French Commercial Code. It details a group of shareholders (a 'concert') updating their intentions regarding the composition of the Board of Directors of OSE IMMUNOTHERAPEUTICS ahead of an upcoming General Meeting. This type of filing, which concerns significant shareholding groups and their voting intentions/board influence, falls under the category of Major Shareholding Notification (MRQ) as it relates to the disclosure of interests and intentions by significant shareholders.
2025-09-16 French
Mise à jour de l’information relative à l’Assemblée Générale du 30 septembre 2025-Constitution d’un pacte réunissant 61 actionnaires fondateurs, historiques, salariés et dirigeants de la Société porta
AGM Information Classification · 98% confidence The document is an announcement regarding an upcoming Annual General Meeting (AGM) scheduled for September 30, 2025. It details a shareholder pact, voting intentions, and instructions for participation (voting methods, contact information). While it relates to an AGM, it is an informational announcement regarding the meeting logistics and shareholder actions rather than the presentation materials used during the meeting itself. Therefore, it is best classified as a Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders regarding the meeting and voting procedures.
2025-09-12 French
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du po
Regulatory Filings Classification · 95% confidence The document is a press release issued by OSE Immunotherapeutics announcing the completion of patient enrollment in a Phase 2 clinical trial (Combi-TED). It provides details on the trial, the patient population, and expected timelines for results. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing of a mandatory nature. As it is a corporate announcement regarding operational/clinical progress, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-09-11 English
Le Conseil d’Administration appelle à soutenir une stratégie créatrice de valeur et une gouvernance ouverte - Publication des documents de convocation à l’Assemblée Générale Mixte du 30 septembre 2025
AGM Information Classification · 98% confidence The document is a formal communication from OSE Immunotherapeutics regarding their upcoming Annual General Meeting (AGM) scheduled for September 30, 2025. It details the board's recommendations on voting resolutions, addresses a proxy contest from a minority shareholder group, and provides instructions on how shareholders can access meeting materials and vote. While it contains information about the meeting, it is a solicitation of support and a presentation of the board's position to shareholders, which fits the definition of Proxy Solicitation & Information Statement (PSI).
2025-09-09 French
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025
AGM Information Classification · 98% confidence The document is a press release from OSE Immunotherapeutics regarding their upcoming Combined Annual General Meeting (AGM) on September 30, 2025. It outlines the Board's strategic recommendations, voting instructions for shareholders, and information on how to access the official convening notice and preparatory documents. While it discusses the AGM, it is a communication piece (a press release) intended to solicit support and provide information ahead of the meeting, rather than the official meeting minutes or the full set of proxy materials themselves. Under the provided definitions, this fits best as a Proxy Solicitation & Information Statement (PSI) as it explicitly urges shareholders to vote in a specific manner on resolutions and provides context for those votes.
2025-09-09 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.